Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome

Maxime Rossi¹,²,⁎, Michael Piagnerelli³,⁴, Alain Van Meerhaeghe⁵, Karim Zouaoui Boudjeltia⁶

¹ Institute for Medical Immunology (IMI), Université Libre de Bruxelles, Gosselies, Belgium
² Department of Urology, CHU de Charleroi, Université Libre de Bruxelles, Charleroi, Belgium
³ Department of Intensive Care, CHU de Charleroi, Université Libre de Bruxelles, Charleroi, Belgium
⁴ Laboratory of Experimental Medicine (ULB 222 Unit), CHU de Charleroi, A. Vésale Hospital, Université Libre de Bruxelles, Montigny-le-Tilleul, Belgium

ARTICLE INFO
Keywords:
COVID-19
SARS-CoV-2
heme oxygenase-1 (HO-1)
Hemin
Cytokine storm
Acute respiratory distress syndrome (ARDS)

ABSTRACT
The outbreak of coronavirus disease 2019 (COVID-19) requires urgent need for effective treatment. Severe COVID-19 is characterized by a cytokine storm syndrome with subsequent multiple organ failure (MOF) and acute respiratory distress syndrome (ARDS), which may lead to intensive care unit and increased risk of death.

While awaiting a vaccine, targeting COVID-19-induced cytokine storm syndrome appears currently as the efficient strategy to reduce the mortality of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The stress-responsive enzyme, heme oxygenase-1 (HO-1) is largely known to protect against inflammatory response in animal models. HO-1 is induced by hemin, a well-tolerated molecule, used for decades in the treatment of acute intermittent porphyria. Experimental studies showed that hemin-induced HO-1 mitigates cytokine storm and lung injury in mouse models of sepsis and renal ischemia-reperfusion injury. Furthermore, HO-1 may also control numerous viral infections by inhibiting virus replication.

In this context, we suggest the hypothesis that HO-1 cytoprotective pathway might be a promising target to control SARS-CoV-2 infection and mitigate COVID-19-induced cytokine storm and subsequent ARDS.

Background

COVID-19 and cytokine storm

The coronavirus disease 2019 (COVID-19) was first described in Wuhan, China, in December 2019 and the outbreak has rapidly spread across the world. COVID-19 is caused by a novel beta-coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2]. Most of COVID-19 cases (about 80%) develop mild symptoms while 5% of infected patients have severe disease characterized by acute respiratory distress syndrome (ARDS) and multiorgan damage [1]. Through the binding of angiotensin-converting enzyme 2 (ACE2) receptor, SARS-CoV-2 targets lung and other organs (e.g., heart, kidney, intestine, brain, liver, and blood vessels), which may lead to subsequent multiple organ failure (MOF) and intensive care unit (ICU) requirement [1,2]. The mortality of ICU patients is mainly due to ARDS and increases to 60% [3,4].

Compelling evidence suggest that cytokine storm syndrome plays a critical role in severe COVID-19 [5]. Indeed, proinflammatory cytokines/chemokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-2, IL-6, IL-7, granulocyte-colony stimulating factor (G-CSF), interferon gamma-induced protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein 1-α (MIP-1α) are elevated in plasma of COVID-19 patients, particularly in severe cases [4,6,7]. This cytokine storm may trigger an uncontrolled systemic inflammatory response, which also contributes to ARDS and MOF leading to death [8].

While awaiting a vaccine, targeting COVID-19-induced cytokine storm syndrome appears currently as the efficient strategy to reduce the mortality of SARS-CoV-2 and limit the overload of ICU.

In this context, the use of glucocorticoids as an immunomodulatory therapy remains a current matter of debate. On the one hand, glucocorticoids might exacerbate COVID-19-associated lung injury, but on the other hand, short course of treatment is suggested for moderate-to-severe COVID-19-induced ARDS [5,9].

IL-6 has recently emerged as a key target due to its critical role in
cytokine storm syndrome and subsequent disease severity [10]. Hence, numbers of clinical trials using tocilizumab (IL-6 receptor blockade) have been approved and in progress (e.g., ChiCTR2000029765, NCT04317092, NCT04346355, NCT04335071).

**Heme oxygenase-1 (HO-1)**

Heme oxygenase-1 (HO-1, encoded by Hmox1) is a stress-induced enzyme that metabolizes free heme into carbon monoxide, biliverdin, and iron. Through its byproducts, HO-1 exhibits cytoprotective, anti-apoptotic, and immunomodulatory properties that may modulate diseases involving inflammation [11]. HO-1 controls the immune response, for instance, by stimulating the expression of IL-10, the well-known anti-inflammatory cytokine and by enhancing macrophage polarization toward an anti-inflammatory (i.e., M2) phenotype [12-15]. HO-1 also mediates immune response through IRF3 and subsequent IFNα/β production, which may induce IL-10 and reduce the production of inflammatory cytokines [16]. Interestingly, HO-1 is induced by hemin (i.e. synthetic heme), a molecule which is well tolerated with low rate of side effects and has been approved by the US Food and Drug Administration for the treatment of acute intermittent porphyria [17,18].

**Hypothesis**

We propose an approach to modulate SARS-CoV-2 infection and the subsequent cytokine storm by stimulating an anti-inflammatory pathway. Based on current literature, hemin-induced HO-1 cytoprotective pathway appears as a consistent target to control COVID-19.

**Evidence supporting HO-1 as a potential target**

**HO-1 as modulator of inflammatory response in animal models**

Sepsis and ischemia-reperfusion injury (IRI) are interesting models to study inflammation. They combine major cell stress, significant burst of free radicals, and strong inflammatory responses comparable to COVID-19-induced cytokine storm, suggesting that findings about these models might be used as potential therapeutic strategy against SARS-CoV-2.

Sepsis is characterized by a systemic inflammatory response syndrome with overexpression of proinflammatory cytokines, which may lead to lethal MOF [19]. In this context, HO-1 has shown protective anti-inflammatory properties [11]. Through down-regulation of proinflammatory cytokines (i.e., IL-1β and TNF-α), HO-1 induction by using hemin protects mice from lethal endotoxemia and sepsis induced by liposaccharide (LPS) or cecal ligation and puncture [19]. Furthermore, overexpression of HO-1 has also been demonstrated protective against LPS-induced lung injury [11].

Preemptive induction of HO-1 by using hemin is largely known to be an efficient protective strategy against renal IRI in animal models [20,21]. Renal IRI also promotes systemic release of pro-inflammatory cytokines (e.g., IL-1β, IL-6, and TNF-α) that induces a systemic inflammatory response, resulting in proinflammatory cells recruitment and remote organ damage, particularly in lung [22].

Basically, hemin-induced HO-1 improves renal outcomes after renal IRI by decreasing level of various renal proinflammatory cytokines, including IL-1β, IL-6, TNF-α, KC (keratinocyte chemoattractant also called CXCL1, a chemokine involved in neutrophils influx), and MCP-1 [20,22]. Moreover, it has been shown that hemin-induced HO-1 reduces IRI-induced cytokine storm and subsequent lung injury by decreasing plasma level of IL-6 and KC, and lung inflammation (neutrophils influx and lung KC) [22].

**Resident- and circulating-macrophages are critical for HO-1 anti-inflammatory properties**

Hemin-mediated protection against renal IRI requires specific expression of HO-1 within myeloid cells (i.e., CD11b- F4/80+ macrophages) [20]. Interestingly, this myeloid cell sub-population was observed in the kidney and spleen, suggesting that protective effects might be provided by both tissue-resident and infiltrating/circulating HO-1+ myeloid cells [20]. In term of lung injury, resident alveolar macrophages (AMs) prevent lung inflammation and repair tissue damage through several anti-inflammatory mechanisms including HO-1 [23]. Then, in vitro hemin significantly induced HO-1 expression in primary rat AMs [23]. Moreover, it was shown that M2 macrophages promote recovery in sepsis-induced lung injury through overexpression of anti-inflammatory cytokines [24]. By inference, tissue-resident AMs expressing HO-1 might explain the mitigation of renal IRI/sepsis-induced lung injury observed with hemin. Altogether, these data show the importance of lung-resident macrophages, which might be targeted by hemin to mitigate local inflammation and subsequent ARDS following cytokine storm.

Otherwise, splenectomy was associated with an exacerbated pro-inflammatory response and lung injury after renal IRI due to decreased splenic IL-10 production, suggesting that circulating macrophages are also involved in the control of lung injury [25]. HO-1+ spleen myeloid cells might therefore reduce cytokine storm and constitute a reservoir that might be recruited to remote injured lung and dampen subsequent ARDS. Accordingly, these observations suggest that hemin-mediated improvement of lung injury following systemic inflammatory response might also be provided by both tissue-resident and infiltrating/circulating HO-1+ M2 macrophages.

**Antiviral effect of HO-1**

A recent study has highlighted the antiviral effect of HO-1 against influenza viruses. Indeed, authors showed that cobalt protoporphyrin (CoPP), a potent HO-1 inducer similar to hemin, inhibits influenza A virus replication through HO-1 interaction with IRF3 and subsequent expression of IFNα/β [26]. A same mechanism was found in human respiratory syncytial virus infection with attenuation of viral replication and lung inflammation upon HO-1 induction and expression of IFNα/β in the infected lung [27]. Note, HO-1-mediated type I IFN response may control numerous of other viral infections, such as hepatitis B/C virus, Ebola virus, and human immunodeficiency virus by inhibiting virus replication [26]. By inference, these data suggest that hemin-induced HO-1 may be also used to overcome the outbreak of COVID-19 by inhibiting SARS-CoV-2 replication.

**Hemin use in humans**

Hemin was shown to increase efficiently HO-1 protein expression and activity in humans [17]. Currently, hemin is only approved for the treatment of acute intermittent porphyria by the US Food and Drug Administration [18]. Interestingly, hemin is a well-tolerated molecule with low rate of adverse effects, such as headache, fever, and phlebitis at the site of infusion [17,18]. Recently, hemin safely induced HO-1 in renal transplant recipients and further studies are expected to determine the impact of HO-1 expression on clinical outcomes [28].

**Discussion**

**Dual effect of hemin**

The timing of hemin administration is a critical point to consider in this hypothesis. Indeed, hemin-induced HO-1 protects against renal IRI when hemin is given preemptively to renal insult (i.e. hemin preconditioning) [20,21]. However, hemin does not protect kidney and...
even worsened renal insult when acute kidney injury is already established [29]. Hemin may therefore have a dual effect, protective or deleterious, depending on the timing of its administration.

**Hemin-induced HO-1 therapy: a polymorphism dependency**

The polymorphism of human Hmox1 gene should be carefully considered. Indeed, polymorphisms of guanosine thymidine dinucleotide (GT)n repeats in the promoter of Hmox1 are inversely correlated with HO-1 mRNA level and enzyme activity [11]. Individuals carrying the long (L) allele [(GT)n ≥ 30] display impaired transcriptional regulation and decreased expression of HO-1 [11]. This genetic variation influences the ability to induce HO-1 and, thereby, hemin treatment efficiency. Of note, HO-1 was found to be elevated in the lungs of patients with ARDS and Hmox1 promoter polymorphisms also influence the occurrence of ARDS [30,31]. Polymorphisms in HO-1 might be involved in the heterogeneity reported in critically ill COVID-19 patients, and it even more influences susceptibility to various human diseases (e.g., cardiovascular disease, necrotizing acute pancreatitis, chronic obstructive pulmonary disease) [11]. Accordingly, these data provide critical information about eventual pharmacologic targeting of HO-1 in COVID-19+ patients.

**Hypothesis testing**

We would perform a clinical study with hospitalized severe COVID-19+ patients, which would be randomized into hemin and placebo groups. Patients would be monitored clinically and by usual laboratory tests and plasma cytokines/chemokines/HO-1 measurement. Although it would be practically difficult, we think that polymorphisms in HO-1 should be considered to assess rigorously hemin treatment efficiency. DNA fragments would be extracted from peripheral blood stem cells, and the Hmox1 locus containing the GT repeat would be amplified by using polymerase chain reaction (PCR).

Based on current knowledge about hemin pharmacology in humans, we propose intravenous dose of 3–4 mg/kg/day (maximum dose of 6 mg/kg/day) similar to that recommended for treating acute intermittent porphyria [17,18]. The duration of the treatment should be considered according to clinical response (e.g. 3–14 days for the treatment of acute intermittent porphyria) [17,18]. Due to its dual effect, hemin should be administered on the onset of respiratory symptoms to prevent ARDS and subsequent overloaded ICU. Hence, we do not recommend hemin use in case of established ARDS because it might worsen the disease based on experimental data [29].

**Conclusion**

With respect to current literature, there is a series of compelling evidence indicating a potential role for hemin-induced HO-1 as a treatment strategy against COVID-19-induced cytokine storm syndrome. Conversely to tocilizumab and glucocorticoids, hemin-induced HO-1 is able to mitigate cytokine storm and subsequent ARDS with a decelerated mechanism, by targeting wide range of proinflammatory mediators in animal models of sepsis and IRI. Moreover, due to its antiviral properties, hemin-induced HO-1 might be an interesting target to control the outbreak of COVID-19 by inhibiting SARS-CoV-2 replication. Obviously, the relevance and translation of animal/in vitro findings to humans require further investigations. However, hemin efficiently induces HO-1 in humans and is used safely for decades in the treatment of acute intermittent porphyria and recently in renal transplant [17,18,28]. Due to the low rate of adverse events, hemin appears to be a safer treatment than glucocorticoids. Furthermore, glucocorticoids might exacerbate COVID-19-associated lung injury [5,9]. Hence, hemin-induced HO-1 might be a harmless, novel, and promising approach for controlling SARS-CoV-2 infection and limiting cytokine storm syndrome with subsequent ARDS following COVID-19.

**Contribution**

MR did the literature search and drafted the paper. MR, MP, AVM, and KZB put forward the hypothesis. MP, AVM, and KZB revised the manuscript.

**Financial support**

No financial support was used for the writing of this manuscript.

**Declaration of interests**

The authors of this manuscript have no conflict of interest to disclose.

**References**

[1] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2019;382(20):1708–20.
[2] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
[3] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respiratory Med 2020.
[4] Ruan Q, Yang K, Wang W, Jiang L, Song L. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020.
[5] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunesuppression. Lancet (London, England) 2020;395(10233):1033–4.
[6] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020;395(10223):497–506.
[7] Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet (London, England) 2020.
[8] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med 2020;8:420–2.
[9] Alhazzani W, Moller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020;46:854–87.
[10] Liu B, Li M, Zhou Z, Guo X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020;102452.
[11] Ryter SW, Choi AM. Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation. Transl Res 2016;177:74–8.
[12] Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interferon-κα in mice. Nat Med 2002;8:240–6.
[13] Chen S, Kapturczak MH, Wasserfall C, et al. Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allologs by a heme oxygenase-dependent pathway. PNAS 2005;102:7251–6.
[14] Naito Y, Takagi T, Higashimura Y. Heme oxygenase-1 and anti-inflammatory M2 macrophages. Arch Biochem Biophys 2014;564:83–8.
[15] Zhang M, Nakamura K, Kageyama S, et al. Myeloid HO-1 modulates macrophage polarization and protects against ischemia-reperfusion injury. JCI Insight 2018;3.
[16] Tzima S, Victoratos P, Kranidiotis A, Alexiou M, Kollias G. Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. J Exp Med 2009;206:1167–79.
[17] Bharucha AE, Kulkarni A, Choi KM, et al. First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans. Clin Pharmacol Ther 2010;87:187–90.
[18] Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005;142:439–50.
[19] Tsoyi K, Lee TY, Lee YS, et al. Heme oxygenase-1 induction and carbon monoxide releasing molecule inhibit lipopolysaccharide (LPS)-induced high mobilility group box 1 release in vitro and improve survival of mice in LPS- and cecal ligation and puncture-induced sepsis model in vivo. Mol Pharmacol 2009;76:173–82.
[20] Rossi M, Thiery A, Delbaeue S, et al. Specific expression of heme oxygenase-1 by myeloid cells modulates renal ischemia-reperfusion injury. Sci Rep 2017;7:197.
[21] Chok MK, Ferlicot S, Conti M, et al. Renoprotective potency of heme oxygenase-1 induction in rat ischemia-reperfusion. Inflamm Allergy Drug Targets 2009;9:252–9.
[22] Rossi M, Delbaeue S, Boumeure Que T, et al. HO-1 mitigates acute kidney injury and subsequent kidney-lung cross-talk. Free Radical Res 2019;53:1105–43.
[23] Hualin C, Wenli X, Dapeng L, Xijing L, Xinsha P, Qingfeng P. The anti-inflammatory mechanism of heme oxygenase-1 induced by hemin in primary rat alveolar macrophages. Inflammation 2012;35:1087–93.
[24] Shen Y, Song J, Wang Y, et al. M2 macrophages promote pulmonary endothelial cells regeneration in sepsis-induced acute lung injury. Ann Transl Med 2019;7:142.
[25] Andres-Hernando A, Altmann C, Anjua N, et al. Spleenectomy exacerbates lung
injury after ischemic acute kidney injury in mice. Am J Physiol Renal Physiol 2011;301:F907–16.

[26] Ma LL, Zhang P, Wang HQ, et al. Heme oxygenase-1 agonist CoPP suppresses influenza virus replication through IRF3-mediated generation of IFN-α/β. Virology 2019;528:80–8.

[27] Espinoza JA, León MA, Céspedes PF, et al. Heme Oxygenase-1 modulates human respiratory syncytial virus replication and lung pathogenesis during infection. J Immunol (Baltimore Md.: 1950) 2017;199:212–23.

[28] Thomas RA, Crepek A, Bellamy CO, McNally SJ, Khuth DC, Marson LP. Hemin preconditioning upregulates heme oxygenase-1 in deceased donor renal transplant recipients: a randomized, controlled, phase IIB trial. Transplantation 2016;100:176–83.

[29] Rossi M, Delhouve S, Wespes E, et al. Dual effect of hemin on renal ischemia-reperfusion injury. Biochem Biophys Res Commun 2018;503:2820–5.

[30] Mumby S, Upton RL, Chen Y, et al. Lung heme oxygenase-1 is elevated in acute respiratory distress syndrome. Crit Care Med 2004;32:1130–5.

[31] Sheu CC, Zhai R, Wang Z, et al. Heme oxygenase-1 microsatellite polymorphism and haplotypes are associated with the development of acute respiratory distress syndrome. Intensive Care Med 2009;35:1343–51.